In May 2024, Argenx, a global immunology company, will be participating in a fireside chat at the BofA Securities 2024 Health Care Conference. The event will feature members of the management team and will be live-streamed on the Investors section of the Argenx website. A replay of the webcast will also be accessible on the website for approximately 90 days after the event.
Argenx is dedicated to translating immunology breakthroughs into innovative antibody-based medicines through its Immunology Innovation Program (IIP). The company has developed and is currently commercializing the first approved neonatal Fc receptor (FcRn) blocker in multiple regions around the world. In addition to this, Argenx is evaluating efgartigimod in various serious autoimmune diseases and advancing several early-stage experimental medicines within its therapeutic franchises.
For more information about Argenx, visit their website at www.argenx.com and follow them on social media platforms like LinkedIn, Twitter, Instagram, Facebook, and YouTube. For media inquiries, please contact Ben Petok at bpetok@argenx.com. For investor-related questions, reach out to Alexandra Roy (US) at aroy@argenx.com or Lynn Elton (EU) at lelton@argenx.com.
